IL2 and acute myeloid leukemia: At present, other ongoing clinical trials are evaluating the efficacy of infusing cytokine-induced memory-like NK cells in the setting of allo-HSCT for AML in association with Donor Lymphocytes Infusion (DLI) or using ALT-803 as an alternative for IL-2 [42,43].